CRISPRi screen identifies FprB as a synergistic target for gallium therapy in Pseudomonas aeruginosa

CRISPRi screen identifies FprB as a synergistic target for gallium therapy in Pseudomonas aeruginosa

Abstract With the rise of antibiotic-resistant bacteria, non-antibiotic therapies like gallium gain increasing attention. Intravenous gallium nitrate is under Phase II clinical trials to treat chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. However, its clinical efficacy is co...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Zhang, Tingting Zhang, Xue Xiao, Yejun Wang, Adam Kawalek, Jinzhao Ou, Anmin Ren, Wenhao Sun, Vincent de Bakker, Yujie Liu, Yuelong Li, Liang Yang, Liang Ye, Ning Jia, Jan-Willem Veening, Xue Liu
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61208-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-61208-z

Similar Items